As psychedelic companies innovate and therapy apps integrate artificial intelligence, some individuals are beginning to use AI chatbots to assist during their psychedelic experiences. One notable case is "Trey," a first responder from Atlanta who turned to the AI-powered journaling app Alterd after struggling with alcoholism for over a decade. In April, while using Alterd as a "tripsitter," he took 700 micrograms of LSD, a significantly higher dose than the typical recreational amount. Post-experience, he noted a profound shift in his cravings, expressing feelings of freedom and self-trust.
Trey described using the app’s "chat with your mind" feature to engage in discussions about his evolving wisdom and the newfound clarity he experienced. Drawing on these interactions, he considers the AI a reflection of his subconscious and an essential aspect of his self-awareness journey.
This trend isn’t isolated to Trey. The use of AI chatbots during psychedelic trips poses the question of a future where such technology could guide experiences traditionally overseen by human therapists. In jurisdictions where psychedelic therapy is not fully legalized, reliance on AI might grow as a cost-effective alternative to expensive in-person treatment, despite warnings from experts. Concerns have been raised regarding the emotional attunement of AI, with researchers cautioning that a disembodied voice may lack the nuanced understanding a human therapist offers, which is critical for effective care during potentially turbulent experiences.
Innovations in this space include the development of prototypes for AI-driven therapy assistants that could one day manage aspects of psychedelic treatment. For instance, an AI-powered therapy chatbot recently underwent trial, showing promising results in improving mental health outcomes, comparable to human therapists for some participants.
Christian Angermayer, founder of Atai Life Sciences, champions the idea of AI complementing human therapists by providing motivational check-ins and enhancing therapeutic support—though he emphasizes the need for trained professionals to oversee the psychedelic process.
While some, like Trey, report beneficial experiences with AI assistance, others highlight the risks. Imbalances in emotional support and the potential for paranoia or psychosis associated with overreliance on AI during intense experiences provoke substantial debate. Peter, a coder from Canada, supplemented his mushroom trip preparation with guidance from ChatGPT, finding that it helped him navigate his thoughts and emotions. During his trip, he experienced significant revelations and appreciated the virtual support during overwhelming moments.
As companies explore creating AI guides to facilitate psychedelic journeys—such as Mindbloom, which pairs AI insights with traditional therapy—concerns remain about the implications of involving intelligence lacking human empathy. Experts call for caution, emphasizing that the nuanced understanding and emotional connection provided by a human therapist is essential, particularly when guiding clients through profound and challenging psychedelic experiences.
Despite these risks, the prospect of AI as a therapeutic aide reflects a growing intersection of technology and mental health that continues to evolve, prompting both excitement and caution within the community.
